MCHR1 and depressive disorder: The current meta-analysis suggests that in addition to the treatment of obesity, possible therapeutic targets of MCHR1 antagonists include anxiety disorder, depressive disorder, hypersomnia, sleepiness, male sexual dysfunction, drug addiction, and hypotension.